Published in Lancet Oncol on December 08, 2009
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med (2016) 3.46
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol (2015) 2.60
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol (2013) 2.34
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med (2016) 1.88
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol (2012) 1.69
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Toxicities of Immunotherapy for the Practitioner. J Clin Oncol (2015) 1.50
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol (2013) 1.44
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One (2014) 1.37
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med (2012) 1.32
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm (2010) 1.22
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med (2015) 1.18
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res (2013) 1.16
Immune modulation for cancer therapy. Br J Cancer (2014) 1.15
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol (2014) 1.11
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol (2015) 1.07
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res (2014) 1.06
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med (2011) 1.06
Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer (2014) 1.04
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99
Statistical issues and challenges in immuno-oncology. J Immunother Cancer (2013) 0.99
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther (2014) 0.98
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest (2015) 0.98
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J (2012) 0.97
CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant (2010) 0.97
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis (2016) 0.97
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94
Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol (2013) 0.93
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol (2015) 0.92
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res (2014) 0.92
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes (2012) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol (2015) 0.92
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer (2011) 0.91
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun (2010) 0.91
Stem cells and targeted approaches to melanoma cure. Mol Aspects Med (2013) 0.90
Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res (2015) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys (2016) 0.89
Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer (2012) 0.89
What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) (2012) 0.88
TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res (2015) 0.87
Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol (Pozn) (2013) 0.87
Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med (2015) 0.87
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett (2015) 0.86
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 11.04
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol (2005) 9.42
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Magnetic domain-wall racetrack memory. Science (2008) 8.24
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A (2001) 3.29
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04
Chiral spin torque at magnetic domain walls. Nat Nanotechnol (2013) 2.98
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Telemedical wound care using a new generation of mobile telephones: a feasibility study. Arch Dermatol (2005) 2.91
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Dermoscopic examination of nail pigmentation. Arch Dermatol (2002) 2.83
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Current-controlled magnetic domain-wall nanowire shift register. Science (2008) 2.68
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol (2005) 2.55
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol (2011) 2.52
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother (2004) 2.12
Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol (2004) 2.08
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst (2004) 2.06
Induction of autophagy is essential for monocyte-macrophage differentiation. Blood (2012) 2.05
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03